Mounjaro Cost 2026: Without Insurance, Savings Card & Highest Dose

Mounjaro retail cash-pay is approximately $1,069 for a 28-day supply (similar to Zepbound, lower than Wegovy). With the Mounjaro Savings Card, eligible commercially insured patients pay as low as $25/month. Mounjaro is FDA-approved for type 2 diabetes (not weight loss — that's Zepbound, which is the same molecule tirzepatide). Diabetes coverage is broader than weight-loss coverage, so insurance + savings card path is more accessible for Mounjaro than for Zepbound.

Mounjaro retail without insurance: $1,069/month. Without the savings card, cash-pay options are limited because Mounjaro is the diabetes-indication branding (Zepbound is the weight-loss branding of the same tirzepatide molecule). For weight-loss patients, switching to Zepbound is typically more accessible — LillyDirect sells Zepbound vials at $399/month cash-pay. For diabetes patients without insurance, compounded tirzepatide ($179-249/month from state-licensed 503A pharmacies) is the cheapest legitimate path.

The maximum FDA-approved Mounjaro dose is 15mg weekly, reached at week 21 in standard titration. Doses increase every 4 weeks: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg. The minimum effective therapeutic dose for most diabetes patients is 5mg or 7.5mg. The highest dose (15mg) is typically reserved for patients with significant remaining glycemic control needs and who tolerate the higher doses.

Same molecule (tirzepatide), different FDA-approved indications and branding. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management. Insurance coverage differs significantly: Mounjaro (diabetes indication) is broadly covered by commercial insurance and Medicare Part D; Zepbound (weight-loss indication) has more restrictive coverage. For patients with both diabetes and obesity, prescribers often write Mounjaro because the broader insurance coverage makes it cheaper to access.

The Mounjaro Savings Card is for diabetes treatment. Eligibility requires a documented type 2 diabetes diagnosis. Weight-loss patients without diabetes should switch to Zepbound (same molecule, different indication) and use the Zepbound Savings Card. Some patients with prediabetes or insulin resistance may qualify for Mounjaro coverage; verify with your prescriber whether your specific situation supports the diabetes indication.

Yes. Major telehealth platforms (Hims, Henry Meds, Ro) prescribe Mounjaro for patients with type 2 diabetes diagnosis. Tirzepatide is not a controlled substance, so federal Ryan Haight Act doesn't apply. Telehealth platforms with dedicated PA teams handle prior authorization (typical timeline 1-3 weeks) plus medication shipment. Total cost ~$200-400/month with the savings card applied through the platform's pharmacy partner.

Yes. Lilly Cares Foundation provides free Mounjaro to income-qualified uninsured patients (typically household income below 400% of federal poverty level) with documented type 2 diabetes. Application takes 4-8 weeks. For most uninsured patients, the savings card path with telehealth ($25/month after card) is faster than navigating PAP. PAPs remain the right path for patients who cannot afford even the savings-card cost.